37707-72-5

Basic information

• Product Name: 1-(6,7-dimethoxynaphthalen-2-yl)ethanone
• CAS NO: 37707-72-5
• Molecular Formula: C₁₄H₁₄O₃
• Molecular Weight: 230.2592
• Mol File: 37707-72-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 366.8°C at 760 mmHg
• Flash Point: 167°C
• Density: 1.133g/cm³
• Vapor Pressure: 1.43E-05mmHg at 25°C
• Refractive Index: 1.578
• CAS DataBase Reference: 1-(6,7-dimethoxynaphthalen-2-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6,7-dimethoxynaphthalen-2-yl)ethanone(37707-72-5)
• EPA Substance Registry System: 1-(6,7-dimethoxynaphthalen-2-yl)ethanone(37707-72-5)

Safety Data

• Hazardous Substances Data: 37707-72-5(Hazardous Substances Data)

Usage

General Description

1-(6,7-dimethoxynaphthalen-2-yl)ethanone, also known as dimethyl-2-naphthyl ketone, is a chemical compound with a molecular formula C14H14O3. It is a white crystalline solid that is commonly used as a fragrance and flavor ingredient in various products, including perfumes, cosmetics, and food items. It is a derivative of naphthalene and is commonly synthesized through the Friedel-Crafts acylation reaction. The chemical is known for its sweet, floral, and woody odor, making it a popular choice for adding fragrance to a wide range of consumer products. It is also used in the manufacturing of pharmaceuticals and as a chemical intermediate in organic synthesis. Additionally, it has been studied for its potential biological activities, including as an antioxidant and anti-inflammatory agent.

Upstream product

• 10103-06-7 2,3-dimethoxynaphthalene 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 
• 76885-52-4 1-(4,5-Dimethoxy-11-oxa-tricyclo[6.2.1.0^2,7]undeca-2⁽⁷⁾,3,5-trien-9-yl)-ethanone 
• 92-44-4 2,3-naphthalenediol 

Downstream Products

• 37707-78-1 6,7-Dimethoxy-naphthalene-2-carboxylic Acid 
• 118199-17-0 6-Acetyl-2,3-dihydroxynaphthalene 
• 113458-95-0 6,7-dihydroxy-2-naphthalenecarboxylic acid 
• 13575-86-5 ADTN hydrobromide 
• 80536-56-7 benzyl N-(1,2,3,4-tetrahydro-6,7-dimethoxynaphthalene-2-yl)carbamate 
• 136944-52-0 6-Ethoxy-2,3-dihydroxynaphthalene 
• 136944-48-4 N-n-Butyl-6,7-dihydroxy-2-naphthamide 
• 136944-50-8 N-n-Octyl-6,7-dihydroxy-2-naphthamide 
• 136944-47-3 6,7-Dimethoxy-naphthalene-2-carboxylic acid octylamide 
• 136944-51-9 6,7-Dibenzyloxy-2-naphthol 
• 118199-16-9 6-Acetyl-2,3-dibenzyloxynaphthalene 
• 76886-86-7 6,7-dimethoxy-2-naphthoic acid methyl ester 
• 37707-79-2 6,7-Dimethoxy-2-naphthylmethanol 
• 66920-80-7 6,7-dimethoxy-2-naphthaldehyde 

Relevant articles and documents

In silico design and synthesis of N-arylalkanyl 2-naphthamides as a new class of non-purine xanthine oxidase inhibitors

A series of N-arylalkanyl 2-naphthamides (Xa~e), which were predicted from virtual molecular docking on a built xanthine oxidase template as potential inhibitors, were synthesized. Their inhibitory activity against xanthine oxidase was assayed. Among these prepared, compounds Xb (IC50 13.6?μM), Xc (IC50 13.1?μM), and Xd (IC50 12.5?μM) showed comparable inhibitory activity to allopurinol (IC50 22.1?μM). The in vitro assay result correlated well with molecular docking scores, ΔG?=??16.99, ?17.66, and ?17.13 Kcal/mol, respectively. On the potassium oxonate-induced hyperuricemic mice model, oral administration of Xc-Ac (40 mg/ Kg), the per-O-acetylated Xc, could reduce the blood uric acid level by 60% in comparison to the normal control group and is statistically significant (p .01) while compared with the hyperuricemic mice group.

Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives

SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values.

NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)

Where Y, R1-R8 and R101-R108 are as defined in the specification. Compounds of formula (II) and methods of inhibiting the cytokine or biological activity of Macrophage Migrating Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as part of a combination therapy.